This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
by Zacks Equity Research
Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.
Strength Seen in Elanco Animal Health Incorporated (ELAN): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Elanco Animal Health Incorporated (ELAN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Elanco Animal Health Incorporated (ELAN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's Why Elanco Animal Health Incorporated (ELAN) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Elanco Animal Health Incorporated (ELAN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Implied Volatility Surging for Elanco (ELAN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Elanco (ELAN) stock based on the movements in the options market lately.
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
by Zacks Equity Research
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.
New Strong Buy Stocks for September 19th
by Zacks Equity Research
DHI, DVA, KMTUY, ELAN and BWMX have been added to the Zacks Rank #1 (Strong Buy) List on September 19, 2023.
Best Value Stocks to Buy for September 19th
by Zacks Equity Research
DHI, KMTUY and ELAN made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 19, 2023.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Stock Market News for Aug 8, 2023
by Zacks Equity Research
Wall Street rebounded on Monday, regaining some of the ground lost last week, as investors digested earnings reports from a batch of companies and waited for key inflation readings scheduled for release later this week.
Elanco Animal Health Incorporated (ELAN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 260% and 2.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7% and 1.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Stock Jumps 11.7%: Will It Continue to Soar?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 55.17% and 5.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 46.30% and 1.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aveanna Healthcare (AVAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Elanco Animal Health Incorporated (ELAN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Elanco (ELAN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Elanco (ELAN) stock based on the movements in the options market lately.
Elanco Animal Health Incorporated (ELAN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 46.15% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.